Literature DB >> 8286188

Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.

M J McKeage1, G Abel, L R Kelland, K R Harrap.   

Abstract

Intrinsic resistance to existing clinical platinum drugs is a major cause of treatment failure; moreover, these agents have the drawbacks of cross-resistance and intravenous administration. The mechanism of intrinsic cisplatin resistance and the mechanism of circumvention of intrinsic resistance by a member (JM221) of the ammine/amine platinum (IV) dicarboxylate class of platinum complex was studied in intrinsically resistant (SKOV-3) and sensitive (41M) human ovarian carcinoma cell lines. JM221 reduced the cisplatin resistance factor nine- to 2.7-fold, was more potent than cisplatin and showed marked time-dependent cytotoxicity. Cellular platinum accumulation was 20- to 40-fold greater (P < 0.001), and DNA platination was fourfold greater (P < 0.02), immediately following 2 h equimolar exposure to JM221, compared with cisplatin. DNA platinum levels decreased following cisplatin exposure with a half-life approximating 48 h in both lines, while no net removal of DNA-bound platinum was recorded following JM221 exposure. JM221 caused DNA interstrand cross-linking, but this was 10-20% less frequent with JM221 than with cisplatin when expressed as a proportion of total DNA platinum lesions. Cisplatin DNA interstrand cross-linking was twofold greater in the intrinsically sensitive line (41M) than in the resistant line (SKOV-3) over a range of concentrations and time-points. Neither cellular platinum accumulation, levels of DNA platination nor the rate of removal of DNA-bound platinum in the two cell lines related to their ninefold difference in cisplatin sensitivity. Intrinsic cisplatin resistance appears to be attributable to the inhibition of formation of bifunctional DNA lesions, while the circumvention of intrinsic resistance by JM221 seems to be the result of both improved transport properties and circumvention of DNA repair mechanisms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8286188      PMCID: PMC1968778          DOI: 10.1038/bjc.1994.1

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

Review 2.  Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

Authors:  P A Andrews; S B Howell
Journal:  Cancer Cells       Date:  1990-02

3.  Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

Authors:  D S Alberts; S Green; E V Hannigan; R O'Toole; D Stock-Novack; P Anderson; E A Surwit; V K Malvlya; W A Nahhas; C J Jolles
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

4.  Phase I study of oxaliplatin in patients with advanced cancer.

Authors:  J M Extra; M Espie; F Calvo; C Ferme; L Mignot; M Marty
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

Authors:  R J Knox; F Friedlos; D A Lydall; J J Roberts
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

6.  Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; B A Murrer; G Abel; C M Giandomenico; P Mistry; K R Harrap
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

7.  ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.

Authors:  M Dabholkar; F Bostick-Bruton; C Weber; V A Bohr; C Egwuagu; E Reed
Journal:  J Natl Cancer Inst       Date:  1992-10-07       Impact factor: 13.506

8.  Cisplatin/carboplatin cross-resistance in ovarian cancer.

Authors:  M E Gore; I Fryatt; E Wiltshaw; T Dawson; B A Robinson; A H Calvert
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

9.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Authors:  C A Hills; L R Kelland; G Abel; J Siracky; A P Wilson; K R Harrap
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

10.  The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

Authors:  P Mistry; L R Kelland; G Abel; S Sidhar; K R Harrap
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more
  1 in total

1.  Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.

Authors:  S Y Sharp; V Smith; S Hobbs; L R Kelland
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.